Overview

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

Status:
Active, not recruiting

Trial end date:
2029-06-24

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

NSABP Foundation Inc